PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

Steen Gregers Hasselbalch

PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

Translated title of the contribution: PET with amyloid ligands should not be applied routinely in early diagnostics of Alzheimer's disease

Steen Gregers Hasselbalch

Department of Clinical Medicine

Abstract

Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.

Translated title of the contribution	PET with amyloid ligands should not be applied routinely in early diagnostics of Alzheimer's disease
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	177
Issue number	32
Pages (from-to)	V11140610
ISSN	0041-5782
Publication status	Published - 3 Aug 2015

Cite this

@article{957c47b2ec894882a7c8032c693b1ae9,

title = "PET med amyloidligander b{\o}r ikke anvendesrutinem{\ae}ssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview",

abstract = "Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.",

author = "Hasselbalch, {Steen Gregers}",

year = "2015",

month = aug,

day = "3",

language = "Dansk",

volume = "177",

pages = "V11140610",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "32",

}

TY - JOUR

T1 - PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

AU - Hasselbalch, Steen Gregers

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.

AB - Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.

M3 - Tidsskriftartikel

C2 - 26321582

SN - 0041-5782

VL - 177

SP - V11140610

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 32

ER -

PET med amyloidligander bør ikke anvendesrutinemæssigt i tidlig diagnostik af Alzheimerssygdom – en gennemgang af et Cochranereview

Abstract

Fingerprint

Cite this